Detalhe da pesquisa
1.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
N Engl J Med
; 389(20): 1862-1876, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966285
2.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
N Engl J Med
; 387(5): 421-432, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921451
3.
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Alzheimers Dement
; 19(6): 2287-2297, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454709
4.
Gantenerumab in Early Alzheimer's Disease. Reply.
N Engl J Med
; 390(9): 867, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416440
5.
Concern about Tominersen in Patients with Huntington's Disease. Reply.
N Engl J Med
; 390(11): 1059, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38478006
6.
Tominersen in Adults with Manifest Huntington's Disease.
N Engl J Med
; 389(23): 2203-2205, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055260
7.
What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
J Neurochem
; 155(2): 120-136, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277473
8.
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
N Engl J Med
; 370(4): 311-21, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450890
9.
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
N Engl J Med
; 369(4): 341-50, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23883379
10.
A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified.
Stat Med
; 35(9): 1549-57, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26782946
11.
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
BMC Neurol
; 16: 89, 2016 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27276999
12.
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
CNS Spectr
; 21(6): 450-459, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26471212
13.
Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.
Alzheimers Dement
; 12(1): 75-84, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26079412
14.
Molecular neuropsychology: creation of test-specific blood biomarker algorithms.
Dement Geriatr Cogn Disord
; 37(1-2): 45-57, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24107792
15.
Racial and ethnic diversity in global neuroscience clinical trials.
Contemp Clin Trials Commun
; 37: 101255, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38292216
16.
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Nat Med
; 30(4): 1096-1103, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622249
17.
The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results.
BMC Neurol
; 13: 3, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23305293
18.
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
BMC Geriatr
; 13: 56, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23742728
19.
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.
Alzheimers Dement
; 9(3): 338-45, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23102979
20.
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement
; 9(4): 438-44, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23809364